Tag Archives: Lorenzo Biasio

Credit Suisse Maintains Their Buy Rating on Merck & Company (MRK)

In a report released today, Lorenzo Biasio from Credit Suisse maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $95.00. The company’s shares closed last Friday at $77.67. According to TipRanks.com, Biasio

Credit Suisse Reaffirms Their Buy Rating on Coherus Biosciences (CHRS)

Credit Suisse analyst Lorenzo Biasio maintained a Buy rating on Coherus Biosciences (CHRS – Research Report) today and set a price target of $36.00. The company’s shares closed last Monday at $20.56. According to TipRanks.com, Biasio is a 4-star analyst

Illumina (ILMN) Gets a Buy Rating from Credit Suisse

Credit Suisse analyst Lorenzo Biasio maintained a Buy rating on Illumina (ILMN – Research Report) today and set a price target of $340.00. The company’s shares closed last Monday at $293.41. According to TipRanks.com, Biasio is a 4-star analyst with

Mylan (MYL) Received its Third Buy in a Row

After SunTrust Robinson and Evercore ISI gave Mylan (NASDAQ: MYL) a Buy rating last month, the company received another Buy, this time from Credit Suisse. Analyst Lorenzo Biasio maintained a Buy rating on Mylan today and set a price target

Coherus Biosciences (CHRS) Receives a Buy from Credit Suisse

Credit Suisse analyst Lorenzo Biasio maintained a Buy rating on Coherus Biosciences (CHRS – Research Report) today and set a price target of $36.00. The company’s shares closed last Monday at $19.00. According to TipRanks.com, Biasio is a 3-star analyst

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (NYSE: PFE) and Xoma (NASDAQ: XOMA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report) and Xoma (XOMA – Research Report). Pfizer (PFE) Credit Suisse analyst Lorenzo Biasio maintained a Hold rating on